{"id":56945,"date":"2024-09-09T20:30:47","date_gmt":"2024-09-10T00:30:47","guid":{"rendered":"http:\/\/tuttopavimenti.com\/?p=56945"},"modified":"2024-09-09T20:30:47","modified_gmt":"2024-09-10T00:30:47","slug":"viagra-maker-viatris-beats-q2-estimates-on-branded-and-generic-drug","status":"publish","type":"post","link":"https:\/\/tuttopavimenti.com\/es\/viagra-maker-viatris-beats-q2-estimates-on-branded-and-generic-drug\/","title":{"rendered":"Viagra-maker Viatris beats Q2 estimates on branded and generic drug…"},"content":{"rendered":"

Aug 8 (Reuters) – Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, \ube44\uc544\uadf8\ub77c \uad6c\ub9e4 \uc0ac\uc774\ud2b8<\/a> driven by strong demand for the Viagra-maker’s off-patent branded and generic drugs.<\/p>\n

Shares of the company were up 3.6% in premarket trade.<\/u><\/b><\/p>\n

The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including Breyna – a biosimilar to Astrazeneca’s asthma drug Symbicort – to between $500 million and \ube44\uc544\uadf8\ub77c \uad6c\ub9e4 \uc0ac\uc774\ud2b8<\/a> $600 million, up from its previous range of $450 million to $550 million.<\/p>\n

Viatris, \ube44\uc544\uadf8\ub77c \uad6c\ub9e4 \uc0ac\uc774\ud2b8<\/a> formed by the merger of Mylan and Pfizer’s Upjohn business, boasts a portfolio of well-known generic branded drugs, such as erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica, and arthritis treatment Celebrex.<\/p>\n

Last year, Viatris said it will<\/u><\/p>\n

divest<\/p>\n

from its over-the-counter<\/a> (OTC) drugs, active pharmaceutical ingredients and women’s health businesses as it wanted streamline focus on three core therapeutic areas – ophthalmology, gastroenterology and dermatology.<\/p>\n

However, the company has retained the rights to Viagra, nasal spray Dymista, and select OTC products in certain markets.<\/p>\n

Due to the OTC divestiture, it now expects 2024 revenue of $14.6 billion to $15.1 billion versus its previous forecast of $14.98 billion to $15.48 billion.<\/p>\n

The company also lowered its annual profit forecast to the range of $2.58 to $2.73 per share, down 7 cents at mid-point.<\/p>\n

Viatris’ second-quarter revenue of $3.80 billion beat Wall Street estimates of $3.78 billion. Revenue from both its branded and generic drug units, excluding sales from divested businesses, increased by 2%.<\/p>\n

On an adjusted basis, the company posted a profit of 69 cents per share, narrowly beating estimates of 68 cents per share. (Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid)\"Pin<\/p>","protected":false},"excerpt":{"rendered":"

Aug 8 (Reuters) – Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, \ube44\uc544\uadf8\ub77c \uad6c\ub9e4 \uc0ac\uc774\ud2b8 driven by strong demand for the Viagra-maker’s off-patent branded and generic drugs. Shares of the company were up 3.6% in premarket trade. The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including […]<\/p>\n","protected":false},"author":57155,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[8577],"tags":[8597],"class_list":["post-56945","post","type-post","status-publish","format-standard","hentry","category-drug-medicine","tag-8597"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t